Are Settlements in Patent Litigation Collusive? Evidence from Paragraph IV Challenges
Author
Abstract
Suggested Citation
Note: EH LE
Download full text from publisher
References listed on IDEAS
- Lanjouw, Jean O & Schankerman, Mark, 2001. "Characteristics of Patent Litigation: A Window on Competition," RAND Journal of Economics, The RAND Corporation, vol. 32(1), pages 129-151, Spring.
- Farasat A.S. Bokhari, 2013.
"What Is The Price Of Pay-To-Delay Deals?,"
Journal of Competition Law and Economics, Oxford University Press, vol. 9(3), pages 739-753.
- Farasat A.S. Bokhari, 2013. "What is the price of pay-to-delay deals?," Working Paper series, University of East Anglia, Centre for Competition Policy (CCP) 2013-01, Centre for Competition Policy, University of East Anglia, Norwich, UK..
- Shapiro, Carl, 2003.
"Antitrust Limits to Patent Settlements,"
RAND Journal of Economics, The RAND Corporation, vol. 34(2), pages 391-411, Summer.
- Shapiro, Carl, 2001. "Antitrust Limits to Patent Settlements," Competition Policy Center, Working Paper Series qt87s5j911, Competition Policy Center, Institute for Business and Economic Research, UC Berkeley.
- Carl Shapiro, 2003. "Antitrust Limits to Patent Settlements," Law and Economics 0303004, University Library of Munich, Germany.
- Hemphill, C. Scott & Sampat, Bhaven N., 2012. "Evergreening, patent challenges, and effective market life in pharmaceuticals," Journal of Health Economics, Elsevier, vol. 31(2), pages 327-339.
- Henry G. Grabowski & Margaret Kyle, 2007. "Generic competition and market exclusivity periods in pharmaceuticals," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 491-502.
- Lakdawalla, Darius & Sood, Neeraj, 2013.
"Health insurance as a two-part pricing contract,"
Journal of Public Economics, Elsevier, vol. 102(C), pages 1-12.
- Darius Lakdawalla & Neeraj Sood, 2006. "Health Insurance as a Two-Part Pricing Contract," NBER Working Papers 12681, National Bureau of Economic Research, Inc.
- Jeremy Bulow, 2004. "The Gaming of Pharmaceutical Patents," NBER Chapters, in: Innovation Policy and the Economy, Volume 4, pages 145-187, National Bureau of Economic Research, Inc.
- Douglas Staiger & James H. Stock, 1997.
"Instrumental Variables Regression with Weak Instruments,"
Econometrica, Econometric Society, vol. 65(3), pages 557-586, May.
- Douglas Staiger & James H. Stock, 1994. "Instrumental Variables Regression with Weak Instruments," NBER Technical Working Papers 0151, National Bureau of Economic Research, Inc.
- Panattoni, Laura E., 2011. "The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms," Journal of Health Economics, Elsevier, vol. 30(1), pages 126-145, January.
- Blume-Kohout, Margaret E. & Sood, Neeraj, 2013. "Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development," Journal of Public Economics, Elsevier, vol. 97(C), pages 327-336.
- Daron Acemoglu & Joshua Linn, 2004.
"Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,"
The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 119(3), pages 1049-1090.
- Daron Acemoglu & Joshua Linn, 2003. "Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry," NBER Working Papers 10038, National Bureau of Economic Research, Inc.
- Daron Acemoglu & Joshua Linn, 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," Levine's Working Paper Archive 228400000000000002, David K. Levine.
- Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2016.
"Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry,"
RAND Journal of Economics, RAND Corporation, vol. 47(4), pages 857-890, November.
- Lee G. Branstetter & Chirantan Chatterjee & Matthew Higgins, 2011. "Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry," NBER Working Papers 17188, National Bureau of Economic Research, Inc.
- Keith M. Drake & Martha A. Starr & Thomas McGuire, 2014. "Do "Reverse Payment" Settlements of Brand-Generic Patent Disputes in the Pharmaceutical Industry Constitute an Anticompetitive Pay for Delay?," NBER Working Papers 20292, National Bureau of Economic Research, Inc.
- Atanu Saha & Henry Grabowski & Howard Birnbaum & Paul Greenberg & Oded Bizan, 2006. "Generic Competition in the US Pharmaceutical Industry," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 13(1), pages 15-38.
- Haiden Huskamp & Julie Donohue & Catherine Koss & Ernst Berndt & Richard Frank, 2008. "Generic Entry, Reformulations and Promotion of SSRIs in the US," PharmacoEconomics, Springer, vol. 26(7), pages 603-616, July.
- Filson, Darren & Oweis, Ahmed, 2010. "The impacts of the rise of Paragraph IV challenges on startup alliance formation and firm value in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 29(4), pages 575-584, July.
- Darius Lakdawalla & Tomas Philipson, 2012. "Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets," Journal of Law and Economics, University of Chicago Press, vol. 55(1), pages 151-187.
- Amy Finkelstein, 2004. "Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry," The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 119(2), pages 527-564.
- Ernst R. Berndt & Margaret Kyle & Davina Ling, 2003. "The Long Shadow of Patent Expiration. Generic Entry and Rx-to-OTC Switches," NBER Chapters, in: Scanner Data and Price Indexes, pages 229-267, National Bureau of Economic Research, Inc.
- David Reiffen & Michael R. Ward, 2005. "Generic Drug Industry Dynamics," The Review of Economics and Statistics, MIT Press, vol. 87(1), pages 37-49, February.
- Grabowski, Henry G. & Vernon, John M., 1994. "Returns to R&D on new drug introductions in the 1980s," Journal of Health Economics, Elsevier, vol. 13(4), pages 383-406.
- Miceli, Thomas J., 1997. "Economics of the Law: Torts, Contracts, Property, Litigation," OUP Catalogue, Oxford University Press, number 9780195103908.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Hovenkamp, Erik & Lemus, Jorge, 2018. "Delayed entry settlements at the patent office," International Review of Law and Economics, Elsevier, vol. 54(C), pages 30-38.
- Michael D. Frakes & Melissa F. Wasserman, 2020. "Investing in Ex Ante Regulation: Evidence from Pharmaceutical Patent Examination," NBER Working Papers 27579, National Bureau of Economic Research, Inc.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Branstetter, Lee & Chatterjee, Chirantan & Higgins, Matthew J., 2022.
"Generic competition and the incentives for early-stage pharmaceutical innovation,"
Research Policy, Elsevier, vol. 51(10).
- Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2014. "Generic Competition and the Incentives for Early-Stage Pharmaceutical Innovation," NBER Working Papers 20532, National Bureau of Economic Research, Inc.
- Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2016.
"Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry,"
RAND Journal of Economics, RAND Corporation, vol. 47(4), pages 857-890, November.
- Lee G. Branstetter & Chirantan Chatterjee & Matthew Higgins, 2011. "Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry," NBER Working Papers 17188, National Bureau of Economic Research, Inc.
- Murray L. Aitken & Ernst R. Berndt & Barry Bosworth & Iain M. Cockburn & Richard Frank & Michael Kleinrock & Bradley T. Shapiro, 2013.
"The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales following Loss of Exclusivity,"
NBER Chapters, in: Measuring and Modeling Health Care Costs, pages 243-271,
National Bureau of Economic Research, Inc.
- Murray L. Aitken & Ernst R. Berndt & Barry Bosworth & Iain M. Cockburn & Richard Frank & Michael Kleinrock & Bradley T. Shapiro, 2013. "The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales Following Loss of Exclusivity," NBER Working Papers 19487, National Bureau of Economic Research, Inc.
- Michael D. Frakes & Melissa F. Wasserman, 2020. "Investing in Ex Ante Regulation: Evidence from Pharmaceutical Patent Examination," NBER Working Papers 27579, National Bureau of Economic Research, Inc.
- Matthew J. Higgins & Mathias J. Kronlund & Ji Min Park & Joshua Pollet, 2020. "The Role of Assets In Place: Loss of Market Exclusivity and Investment," NBER Working Papers 27588, National Bureau of Economic Research, Inc.
- Kyle, Margaret K., 2022. "Incentives for pharmaceutical innovation: What’s working, what’s lacking," International Journal of Industrial Organization, Elsevier, vol. 84(C).
- Hemphill, C. Scott & Sampat, Bhaven N., 2012. "Evergreening, patent challenges, and effective market life in pharmaceuticals," Journal of Health Economics, Elsevier, vol. 31(2), pages 327-339.
- Aggarwal, Mayank & Chakrabarti, Anindya S. & Chatterjee, Chirantan & Higgins, Matthew J., 2023.
"Research and market structure: Evidence from an antibiotic-resistant pathogenic outbreak,"
Research Policy, Elsevier, vol. 52(1).
- Mayank Aggarwal & Anindya Chakrabarti & Chirantan Chatterjee & Matthew J. Higgins, 2021. "Research and Market Structure: Evidence from an Antibiotic-Resistant Pathogenic Outbreak," NBER Working Papers 28840, National Bureau of Economic Research, Inc.
- Higgins, Matthew J. & Yan, Xin & Chatterjee, Chirantan, 2021.
"Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling,"
Research Policy, Elsevier, vol. 50(1).
- Matthew J. Higgins & Xin Yan & Chirantan Chatterjee, 2018. "Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling," NBER Working Papers 24957, National Bureau of Economic Research, Inc.
- Volker Grossmann, 2021. "Medical Innovations and Ageing: A Health Economics Perspective," CESifo Working Paper Series 9387, CESifo.
- Eric Budish & Benjamin Roin & Heidi Williams, 2013. "Do fixed patent terms distort innovation? Evidence from cancer clinical trials," Discussion Papers 13-001, Stanford Institute for Economic Policy Research.
- Castanheira, Micael & Ornaghi, Carmine & Siotis, Georges, 2019.
"The unexpected consequences of generic entry,"
Journal of Health Economics, Elsevier, vol. 68(C).
- Micael Castanheira De Moura & Carmine Ornaghi & Georges Siotis, 2019. "The Unexpected Consequences of Generic Entry," Working Papers ECARES 2019-21, ULB -- Universite Libre de Bruxelles.
- Micael Castanheira De Moura & Georges Siotis & Carmine Ornaghi, 2019. "The Unexpected Consequences of Generic Entry," ULB Institutional Repository 2013/298643, ULB -- Universite Libre de Bruxelles.
- Berndt, Ernst R. & Dubois, Pierre, 2012.
"Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010,"
IDEI Working Papers
702, Institut d'Économie Industrielle (IDEI), Toulouse.
- Berndt, Ernst R & Dubois, Pierre, 2012. "Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010," CEPR Discussion Papers 9140, C.E.P.R. Discussion Papers.
- Berndt, Ernst R. & Dubois, Pierre, 2012. "Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010," TSE Working Papers 12-283, Toulouse School of Economics (TSE).
- Appelt, Silvia, 2010. "Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry," Discussion Papers in Economics 11476, University of Munich, Department of Economics.
- Eric Budish & Benjamin N. Roin & Heidi Williams, 2015.
"Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials,"
American Economic Review, American Economic Association, vol. 105(7), pages 2044-2085, July.
- Eric Budish & Benjamin N. Roin & Heidi Williams, 2013. "Do firms underinvest in long-term research? Evidence from cancer clinical trials," NBER Working Papers 19430, National Bureau of Economic Research, Inc.
- Beerli, Andreas & Weiss, Franziska J. & Zilibotti, Fabrizio & Zweimüller, Josef, 2020.
"Demand forces of technical change evidence from the Chinese manufacturing industry,"
China Economic Review, Elsevier, vol. 60(C).
- Beerli, Andreas & Weiss, Franziska & Zilibotti, Fabrizio & Zweimüller, Josef, 2013. "Demand Forces of Technical Change Evidence from the Chinese Manufacturing Industry," VfS Annual Conference 2013 (Duesseldorf): Competition Policy and Regulation in a Global Economic Order 79980, Verein für Socialpolitik / German Economic Association.
- Andreas Beerli & Franziska J. Weiss & Fabrizio Zilibotti, 2018. "Demand forces of technical change: evidence from the Chinese manufacturing industry," ECON - Working Papers 277, Department of Economics - University of Zurich.
- Farasat A.S. Bokhari & Weijie Yan, 2020.
"Product line extensions under the threat of entry: evidence from the UK pharmaceuticals market,"
Working Paper series, University of East Anglia, Centre for Competition Policy (CCP)
2020-04, Centre for Competition Policy, University of East Anglia, Norwich, UK..
- Bokhari, Farasat A. S. & Yan, Weijie, 2020. "Product line extensions under the threat of entry: evidence from the UK pharmaceuticals market," Papers WP678, Economic and Social Research Institute (ESRI).
- C. Scott Hemphill & Bhaven N. Sampat, 2011. "When Do Generics Challenge Drug Patents?," Journal of Empirical Legal Studies, John Wiley & Sons, vol. 8(4), pages 613-649, December.
- Anton‐Giulio Manganelli, 2021. "Reverse payments, patent strength, and asymmetric information," Health Economics, John Wiley & Sons, Ltd., vol. 30(1), pages 20-35, January.
- Hu, Mei-Ying & Lu, You-Xun & Lai, Ching-chong, 2023.
"Patent term extensions and commercialization lags in the pharmaceutical industry: A growth-theoretic analysis,"
Journal of Macroeconomics, Elsevier, vol. 76(C).
- Hu, Mei-Ying & Lu, You-Xun & Lai, Ching-Chong, 2022. "Patent term extensions and commercialization lags in the pharmaceutical industry: A growth-theoretic analysis," MPRA Paper 113923, University Library of Munich, Germany.
More about this item
JEL classification:
NEP fields
This paper has been announced in the following NEP Reports:- NEP-COM-2016-05-21 (Industrial Competition)
- NEP-INO-2016-05-21 (Innovation)
- NEP-IPR-2016-05-21 (Intellectual Property Rights)
- NEP-LAW-2016-05-21 (Law and Economics)
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nbr:nberwo:22194. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: the person in charge (email available below). General contact details of provider: https://edirc.repec.org/data/nberrus.html .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.